Target intelligence / Profile preview

Matrix remodeling associated 8 (MXRA8) (MXRA8)

Target
MXRA8
Molecular classification
Cell adhesion molecule, Receptor, Immunoglobulin superfamily
01

Overview

Matrix remodeling associated 8 (MXRA8), also known as Limitrin or DICAM, is a type I transmembrane protein belonging to the immunoglobulin superfamily that serves as a critical cell surface receptor for several alphaviruses (Zhang et al., 2018). In oncology, MXRA8 has been identified as the primary entry mediator for the oncolytic M1 virus, a naturally occurring alphavirus with potent anti-tumor activity (Song et al., 2022). The M1 virus utilizes its envelope proteins to bind directly to the extracellular domains of MXRA8, facilitating viral attachment and subsequent internalization into the host cell via endocytosis. While MXRA8 expression is necessary for viral entry, the oncolytic selectivity of M1 is further governed by the intracellular absence of the antiviral factor ZAP (Zinc finger CCCH-type antiviral protein 1) (Lin et al., 2014). Consequently, high levels of MXRA8 on the surface of cancer cells serve as a vital predictive biomarker for the efficacy of M1-based virotherapy in various solid tumors, including hepatocellular carcinoma and non-small cell lung cancer (Song et al., 2022). Beyond its role in viral pathogenesis, MXRA8 is involved in cell-cell adhesion, angiogenesis, and the structural integrity of the blood-brain barrier (Zhang et al., 2018).

Other names
LimitrinDICAMDual Ig domain-containing cell adhesion moleculeASP3Matrix remodeling-associated protein 8
02

Mechanism of action

The oncolytic virus M1 binds to the extracellular domains of the MXRA8 receptor on the cancer cell surface, which facilitates viral attachment and internalization via clathrin-mediated endocytosis.

03

Biological functions

Cell adhesionViral entry mediatorBlood-brain barrier maintenanceAngiogenesisOsteoclastogenesis regulation
04

Disease associations

CancerInfectionInflammationArthritis
05

Safety considerations

Potential off-target infection of normal tissues expressing MXRA8Viral immunogenicityFormation of neutralizing antibodiesPotential disruption of blood-brain barrier integrity
06

Interacting drugs

Oncolytic virus M1 (OVM)
07

Biomarkers

MXRA8 protein expressionZAP (Zinc finger CCCH-type antiviral protein 1) deficiency

Beyond the preview

Go deeper on Matrix remodeling associated 8 (MXRA8) (MXRA8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matrix remodeling associated 8 (MXRA8) (MXRA8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call